Cargando…

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma

Detalles Bibliográficos
Autores principales:	Houot, Roch, Poeschel, Viola, Altmann, Bettina, Angel, Stephanie, Thurner, Lorenz, Illmer, Thomas, Andre, Marc, Dreyling, Martin, Maisonneuve, Hervé, Tilly, Hervé, Mayer, Stephanie, Casasnovas, Olivier, Le Gouill, Steven, Offner, Fritz, Cartron, Guillaume, Kerkhoff, Andrea, Weber, Thomas, Hoffmann, Joerg, Ziepert, Marita, Klapper, Wolfram, Itti, Emmanuel, Hellwig, Dirk, Natchkebia, Giorgi, de Leval, Laurence, Rosenwald, Andreas, Haioun, Corinne, Dercle, Laurent, Gaulard, Philippe, Held, Gerhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751801/ https://www.ncbi.nlm.nih.gov/pubmed/35028526 http://dx.doi.org/10.1097/HS9.0000000000000672

Ejemplares similares

Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis
por: Thieblemont, Catherine, et al.
Publicado: (2023)

First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial
por: Braulke, Friederike, et al.
Publicado: (2022)

Prospective evaluation of lymphoma response to immunomodulatory therapy criteria in GATA trial from the LYSA group
por: Al Tabaa, Yassine, et al.
Publicado: (2023)

FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials
por: Kaddu-Mulindwa, Dominic, et al.
Publicado: (2021)

Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group
por: Bonnet, Christophe, et al.
Publicado: (2022)

Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study Group
por: Hohloch, Karin, et al.
Publicado: (2020)

Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years
por: Jullien, Maxime, et al.
Publicado: (2021)

Central nervous system relapse in patients over 80 years with diffuse large B‐cell lymphoma: an analysis of two LYSA studies
por: Cabannes‐Hamy, Aurélie, et al.
Publicado: (2018)

S226: EFFICACY OF ANTI-PD1 THERAPY IN RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA: A MATCHED COHORT ANALYSIS FROM THE LYSA
por: Marouf, Amira, et al.
Publicado: (2023)

Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP
por: Bewarder, Moritz, et al.
Publicado: (2023)

Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry
por: Lemoine, Jean, et al.
Publicado: (2023)

P1079: VERY LONG-TERM FOLLOW-UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
por: Sarkozy, Clementine, et al.
Publicado: (2023)

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
por: Morschhauser, Franck, et al.
Publicado: (2022)

Whole body MRI and PET/CT in haematological malignancies
por: Lin, Chieh, et al.
Publicado: (2007)

Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional study
por: Busson, Raphaël, et al.
Publicado: (2019)

Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial
por: Camus, Vincent, et al.
Publicado: (2022)

S238: CLONAL ARCHITECTURE OF RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: AN ANCILLARY STUDY OF THE ORACLE TRIAL, A LYSA STUDY
por: Loyaux, Romain, et al.
Publicado: (2023)

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study
por: Reboursiere, Emilie, et al.
Publicado: (2016)

Development of research integrity in France is on the rise: the introduction of research integrity officers was a progress
por: Maisonneuve, Hervé
Publicado: (2019)

COVID-19 — Journal de Bord — 20/05/2020 — Les médias n’ont pas à juger de la preuve scientifique
por: Maisonneuve, Hervé
Publicado: (2020)

COVID-19 as a source of poor publications
por: Maisonneuve, Hervé
Publicado: (2022)

COVID-19 comme source de mauvaises publications()
por: Maisonneuve, Hervé
Publicado: (2022)

Whole-body diffusion-weighted imaging in lymphoma
por: Lin, C., et al.
Publicado: (2010)

Whole-body DWI in patients with lymphoma: imaging findings, pitfalls, and limitations
por: Rahmouni, Alain, et al.
Publicado: (2014)

Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper
por: Bailly, Sarah, et al.
Publicado: (2022)

Double Hit Lymphoma Diagnosis and Treatment in Europe—A Cross-Sectional Survey of Clinical Practice by the EHA Lymphoma Working Party (EHA LyG)
por: Aurer, Igor, et al.
Publicado: (2020)

EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: Recommendations for the Second Phase of the COVID-19 Pandemic
por: Dreyling, Martin, et al.
Publicado: (2021)

The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma
por: Hanf, Matthieu, et al.
Publicado: (2016)

Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio
por: Toledano, Mathieu N., et al.
Publicado: (2019)

Whole-body diffusion magnetic resonance imaging in the assessment of lymphoma
por: Lin, Chieh, et al.
Publicado: (2012)

Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma
por: Bobée, Victor, et al.
Publicado: (2020)

Correcting the literature: Improvement trends seen in contents of retraction notices
por: Deculllier, Evelyne, et al.
Publicado: (2018)

Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
por: Houot, Roch, et al.
Publicado: (2020)

Extranodal T- and NK-cell lymphomas
por: de Leval, Laurence, et al.
Publicado: (2022)

P1133: SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY.
por: Cartron, G., et al.
Publicado: (2022)

Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial
por: Held, Gerhard, et al.
Publicado: (2023)

What time-lag for a retraction search on PubMed?
por: Decullier, Evelyne, et al.
Publicado: (2014)

Pandémie à SARS-CoV-2 : éthique et intégrité oubliées devant la précipitation pour publier
por: Maisonneuve, Hervé, et al.
Publicado: (2020)

Reproducibility of Baseline Tumour Metabolic Volume Measurements in Diffuse Large B-Cell Lymphoma: Is There a Superior Method?
por: Eude, Florian, et al.
Publicado: (2021)

Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma
por: Le Gallou, Simon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lceinbtaf6va088jsbcvq2k1sf